Last reviewed · How we verify
Rheumatoid Arthritis in Patient at High Ulcer Risk
Approved treatments
- Voltaren · Hisamitsu Pharmaceutical Co., Inc
- Nexium · AstraZeneca
- Cytotec · Pfizer
Diclofenac inhibits COX-1/COX-2 to reduce prostaglandins; misoprostol is PGE1 analog protecting gastric mucosa. - Arthrotec · Pfizer
- Cytotec · Generic (originally Searle/Pfizer)
Synthetic prostaglandin E1 analog that protects gastric mucosa by inhibiting acid secretion and stimulating mucus/bicarbonate, also causes uterine contraction.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Rheumatoid Arthritis in Patient at High Ulcer Risk patent landscape — cliff calendar, originator estates, attackable patents
- Rheumatoid Arthritis in Patient at High Ulcer Risk treatment landscape brief
- Rheumatoid Arthritis in Patient at High Ulcer Risk treatment updates RSS
Frequently asked questions about Rheumatoid Arthritis in Patient at High Ulcer Risk
What drugs treat Rheumatoid Arthritis in Patient at High Ulcer Risk?
Tracked treatments include Voltaren, Nexium, Cytotec, Arthrotec.
What is the treatment for Rheumatoid Arthritis in Patient at High Ulcer Risk?
Standard treatment for Rheumatoid Arthritis in Patient at High Ulcer Risk includes Voltaren, Nexium, Cytotec, Arthrotec. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Rheumatoid Arthritis in Patient at High Ulcer Risk patent cliff · Rheumatoid Arthritis in Patient at High Ulcer Risk CI report
- Treatment: Voltaren · Hisamitsu Pharmaceutical Co., Inc
- Treatment: Nexium · AstraZeneca
- Treatment: Cytotec · Pfizer
- Treatment: Arthrotec · Pfizer
- Treatment: Cytotec · Generic (originally Searle/Pfizer)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing